VYNE Therapeutics YARW
VYNE Therapeutics FY 2020: revenue $21.0M; diluted EPS $141.73
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001566044-21-000010
- Document
- 10-K
- Exhibit 4.1
- Warrants or notes
- Exhibit 10.11
- Material contract
Key figures from this report
These are the numbers VYNE Therapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$21.0MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$255.6MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS$141.73No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported $7.8810-K income statement, on EDGAR
- Cash and cash equivalents$57.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$137.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Rein Therapeutics RNTX public float $32M, Jun 30, 2025
- Insight Molecular Diagnostics IMDX public float $32M, Jun 30, 2025
- Kezar Life Sciences KZR public float $33M, Jun 30, 2025
- Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
- Tempest Therapeutics TPST public float $30M, Jun 30, 2025